Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Latest Opioid Move Aims To 'Reset The Conversation' On Benzodiazepine Combo

Executive Summary

Agency says it now has enough scientific data to act on a citizen petition noting increase in overdose deaths from concomitant prescribing of two drug classes.

Advertisement

Related Content

Generic Abuse Deterrent Opioids: FDA Offers Tier-Based Testing Approach
Opioids And The Limits Of FDA Power
FDA Opioid Action Plan Could Help Clear Califf Nomination Roadblock

Topics

Advertisement
UsernamePublicRestriction

Register

PS119045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel